Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field

FierceBiotechIn next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach

CellDecoding the spatiotemporal development of human meninges

CellFronto-insular circuit mechanisms of accelerated intermittent theta burst stimulation

CellPhysiological brain clearance architecture revealed by neuronal protein tracing

FierceBiotechASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’

Endpoints NewsCan AI do scientific research?; The 'magic bullet' search has faded in immunotherapy; and more

IlluminaIllumina Ducks DNA Sequence Rival's Antitrust Suit, For Now - Law360

BioPharma DiveAt ASCO, Merck makes case for a ‘cornerstone’ cancer drug

BioPharma DiveBristol Myers unveils data for one of its next-gen blood cancer drugs

Clinical OMICsTeclistamab Outperforms Standard Therapy in Relapsed Multiple Myeloma

Clinical OMICsAI Chatbots Do Not Consistently Deliver Accurate Health Responses

FierceBiotechLegend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform